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Abstract
A growing number of emerging HIV-1 recombinants classified as circulating recombinant forms (CRFs) have been identified
in Southeast Asia in recent years, establishing a molecular diversity of increasing complexity in the region. Here, we
constructed a replication-competent HIV-1 clone for CRF33_01B (designated p05MYKL045.1), a newly identified
recombinant comprised of CRF01_AE and subtype B. p05MYKL045.1 was reconstituted by cloning of the near full-length
HIV-1 sequence from a newly-diagnosed individual presumably infected heterosexually in Kuala Lumpur, Malaysia. The
chimeric clone, which contains the 59 LTR (long terminal repeat) region of p93JP-NH1 (a previously isolated CRF01_AE
infectious clone), showed robust viral replication in the human peripheral blood mononuclear cells. This clone
demonstrated robust viral propagation and profound syncytium formation in CD4
+, CXCR4-expressing human glioma NP-2
cells, indicating that p05MYKL045.1 is a CXCR4-using virus. Viral propagation, however, was not detected in various human
T cell lines including MT-2, M8166, Sup-T1, H9, Jurkat, Molt-4 and PM1. p05MYKL045.1 appears to proliferate only in
restricted host range, suggesting that unknown viral and/or cellular host factors may play a role in viral infectivity and
replication in human T cell lines. Availability of a CRF33_01B molecular clone will be useful in facilitating the development of
vaccine candidates that match the HIV-1 strains circulating in Southeast Asia.
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Introduction
The ability of the human immunodeficiency virus type 1 (HIV-1)
to recombine at high frequency is a critical evolutionary feature that
dictates the extensive diversification of HIV-1 [1,2]. Intersubtype
recombination among distinct HIV-1 strains generating various types
of circulating recombinant form (CRF) have been documented
worldwide [3,4] in which CRF01_AE and CRF02_AG are two
major representative recombinants that are found in Southeast Asia
and West Africa, respectively. In the Southeast Asia epidemic,
continual recombination events involving CRF01_AE and subtype B’
(subtype B variant of Thai origin) have formed new radiations of
novel CRFs, including CRF15_01B [5], CRF33_01B [6], and
CRF34_01B [7]. Such vigorous expansion of CRFs in this region
with 4.0 million HIV-1 infections (as of December 2007) [8] results in
epidemiological diversity of growing complexity, a phenomenon that
has become increasingly similar to that observed in the African
continent [9]. Although CRF01_AE remains the dominant circulat-
ing strain, CRF15_01B and CRF33_01B have in recent years been
estimated to cause thousands of infections in Thailand and Malaysia,
respectively [10]. Inorder tofacilitatethedevelopment and validation
of neutralization assays for use in vaccine clinical trials in the region,
reagents and panels of well characterized HIV isolates based on
epidemiologically relevant HIV strains are essential. In this study, we
constructed an infectious DNA clone CRF33_01B that is a major
circulating strain in Malaysia.
Materials and Methods
Virus isolation
EDTA-treated blood specimens were collected from an HIV-
infected individual, a 43-year-old heterosexual male attending the
HIV clinic of the University Malaya Medical Center in Kuala
Lumpur [6]. The patient has given written consent to the use of his
blood samples for research and publication. The serostatus of the
patient was established by enzyme-linked immunosorbent assay
(ELISA) and Western blot analysis in July 2005. The subject was
receiving antiretroviral treatment consisting of zidovudine, lamivu-
dine and efavirenz at the point of blood collection in August 2005,
with plasma viral load and CD4
+ cell count recorded at 4300 HIV
RNA copies/ml and 121 cells/mm
3, respectively. Upon sample
collection, peripheral blood mononuclear cells (PBMCs) were
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(Amersham Biosciences AB, Uppsala, Sweden) according to
manufacturer’s protocol. For virus isolation, PBMCs were co-
cultured with phytohemagglutinin (PHA) (1 mg/ml)-stimulated
CD8
+ T cell-depleted PBMCs (Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany) from HIV-negative healthy donors in RPMI
1640 containing 10% fetal calf serum and interleukin-2 (20 U/ml)
for 30 days. Virus production was monitored by the virion-
associated reverse transcriptase (RT) assay described previously
[11]. HIV-infected PBMCs were harvested and proviral DNA was
isolated with guanidine detergent (Invitrogen, Carlsbad, CA).
Reconstitution of chimeric infectious molecular clone for
CRF33_01B
Nearfull-length proviralDNAwas amplified usingprimerspbsA-
NarI( 5 9-AGT GGCGCCCGAACAGG-39; HXB2634–650)[12]
(palindromic sequence recognized by the specified restriction
enzyme is underlined) and 9KU5B (59-GGT CTG AGG GAT
CTC TAG TTA CCA G-39; HXB2 9666–9690) by Expand Long
Template PCR System (Roche Diagnostic GmbH, Penzberg,
Germany), purified and TA-cloned in the pCR-XL-TOPO vector
(Invitrogen, Carlsbad, CA). Positive clones harboring the near full-
length insert were screened and selected for subcloning into p93JP-
NH1, a previously described replication-competent DNA clone of
CRF01_AE strain (in a modified pBR-SK9 vector containing
multiple cloning sites) that showed robust replication capacity in
various CD4
+, CXCR4/CCR5-expressing cells [13]. Briefly, NarI
and EcoRI digestion (convenient and unique restriction enzyme
cloning sites in both pCR-XL-TOPO and pBR-SK9) was
performed to allow subcloning of near full-length proviral DNA
into the background of p93JP-NH1. Corresponding fragments of
proviralDNA(insert)andp93JP-NH1(vector) were unidirectionally
ligated to generate a chimeric DNA clone with a 59 long terminal
Figure 1. Outline for constructing a replication-competent DNA clone of HIV-1 CRF33_01B (p05MYKL045.1). Near full-length proviral
DNA of CRF33_01B was amplified by long-range PCR using pbsA-NarI and 9KU5B primers and TA-cloned into a pCR-XL-TOPO vector. DNA clone
containing CRF33_01B genome and p93JP-NH1, an infectious clone of CRF01_AE origin [13], were linearized by NarI and EcoRI. The NarI-EcoRI
fragment from the respective CRF33_01B proviral DNA was directionally ligated with the pBR-SK2 vector that contains the p93JP-NH1 59 long
terminal repeat (LTR) to reconstitute a chimeric full-length construct. Each clone was purified and transformed into HeLa cells to determine proviral
replication. Constructs producing non-replicating viruses were then rescued by reconstituting a 3.7 kb proviral fragment (with NcoI and EcoRI sites)
that includes the functional env gene to recover an infectious CRF33_01B clone, designated as p05MYKL045.1. Restriction enzyme sites in the DNA
and the p93JP-NH1-derived 59 LTR region in p05MYKL045.1 (shaded) are indicated. Refer text for complete descriptions.
doi:10.1371/journal.pone.0006666.g001
CRF33_01B Infectious Clone
PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6666Figure 2. Replication kinetics and virological properties of HIV-1 CRF33_01B molecular clone p05MYKL045.1. (A) To test the
replication dynamics of p05MYKL045.1 in human PBMCs, viral stock equivalent to 5610
5 cpm of
32P activity per 100 ml was inoculated into 2610
5
phytohemagglutinin-stimulated CD8
+ T cell-depleted PBMCs. Assay was prepared in triplicate and cells were incubated for 30 days. RT readout
monitored at every 3 days showed peak replication at day 7 and 10 post-infection, with
32P activity of about 2100 cpm/ml of medium. Molecular
clones of various coreceptor usages were used as positive controls (pNL(AD8), CCR5-tropic; pNL4–3, CXCR4-tropic; p93JP-NH1, dual-tropic). (B) Phase-
contrast microscopy of NP-2.CD4.CXCR4 cells infected with p05MYKL045.1 molecular clone. NP-2 cells morphology was examined every 2 days post-
infection. Shown here is day 15 post-infection where profound cytopathic effect (CPE), as evident by the presence of multinuclear giant cells
(syncytium formation) and cell lyses, was observed in NP-2.CD4.CXCR4 cells infected with p05MYKL045.1 (panel C). Similar CPEs were also noted in
control wells infected with p93JP-NH1 (panel B). Negative control (panel A) shows NP-2.CD4.CXCR4 cells mock-infected with virus-free culture
medium. (C) Virus propagation and co-receptor usage of p05MYKL045.1 in human glioma NP-2.CD4.CXCR4 cells. Viral inoculum of 5610
5 cpm of
32P
activity per 100 ml medium was used to infect 5610
3 NP-2.CD4.CXCR4 cells in triplicate in 96-well plates. Virion-associated RT production was
measured at the indicated time points. Peak viral replication of more than 25000 cpm/mlo f
32P activity was observed at day 17 post-infection.
doi:10.1371/journal.pone.0006666.g002
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production, plasmid was transformed into the chemically-compe-
tent One Shot Stbl3 E. coli (Invitrogen, Carlsbad, CA) following the
manufacturer’s protocol, isolated, and purified for genome-specific
sequencing to confirm the presence of the desired insert. To
determine plasmid replication, HeLa cells (5610
4 cells) in 24-well
plate were transfected with 0.4 mg plasmid using FuGENE 6
transfection reagent (Roche Diagnostic GmbH, Penzberg, Ger-
many) and culture supernatant was harvested 2 days post-
transfection for detecting the RT activity. Using the RT-positive
culture supernatant, growth kinetics of each clone was assessed in
CXCR4-or CCR5-expressingCD4
+ human glioma NP-2 cells [14]
to determine: (1) virus infectivity, and (2) coreceptor usage. Briefly,
HeLa cells supernatant containing 5610
5 counts per minute (cpm)
of
32P activity per 100 ml medium was filtered (0.45 mm pore size
filter) and inoculated into 5610
3 NP-2 cells in a 96-well plate.
Culture assay was incubated in triplicate for about 3 weeks post-
infection and cells were microscopically examined for cytopathic
effect (CPE). Viral infectivity was measured by detecting RT
production in culture supernatant every 2 days. Other established
molecular clones of various coreceptor tropisms were included as
positive controls (pNL(AD8), CCR5-tropic [15]; pNL4-3, CXCR4-
tropic [16]; p93JP-NH1, dual-tropic), whereas negative control
wells were mock-infected with culture medium only.
Replication kinetics in human PBMCs and T cell lines
To test the replication kinetics and coreceptor tropism, viral
stock was prepared by transfecting 5 mg HIV-1 clone into 6610
5
HeLa cells using the FuGENE 6 transfection reagent (Roche
Diagnostic GmbH, Penzberg, Germany). Culture supernatant was
harvested 2 days post-transfection. The production of viral RNA in
situ was measured by RT assay, and virus containing supernatant
was filtered and stored at –80uC until use. To examine the growth
kinetics in PBMCs, 100 ml medium containing 2610
5 of CD8
+ T
cell-depleted, PHA-activated PBMCs from healthy donors were
inoculated with viral stock in a 96-well plate. Virus containing
supernatant equivalent to
32P activity of 5610
5 cpm per 100 ml
were used for infection assay. After overnight adsorption, cultures
were washed twice and fresh RPMI 1640 medium containing 10%
fetal calf serum and interleukin-2 (20 U/ml) was added to a final
volume of 200 ml. Each assay was prepared in triplicate. Culture
medium was harvested for RT assay and replenished with fresh
medium every 3 days until 30 days post-infection. In addition to
human PBMCs, viral propagation was tested in CD4
+ human T
cell lines, including MT-2, M8166, Sup-T1, H9, Jurkat, Molt-4
and PM1, and also CEMx174. Similar to PBMCs, 2610
4 of these
cells were inoculated with virus stock under the same experimental
conditions and settings, and virion-associated RT activities were
measured every 3 days for 30 days post-infection.
Phylogenetic and recombination analysis
Near full-length genome of the construct was sequenced using
primer walking method described previously [6]. Phylogenetic tree
was reconstructed to elucidate the genetic relationship of the
construct with its primary isolate, other CRF33_01B, CRF15_01B
and CRF33_01B reference sequences. In addition, parental
Figure 3. Phylogenetic and recombination analysis of HIV-1 CRF33_01B molecular clone p05MYKL045.1. (A) Phylogenetic
reconstructions of HIV-1 CRF01_AE, subtype B’, CRF33_01B and other CRF01_AE/B’ recombinants of Southeast Asian origin. Near full-length
nucleotide sequences were aligned and adjusted manually. Hypervariable and ambiguous sequences along the genome that could not be aligned
were stripped. Cladogram was plotted using neighbor-joining method implemented in MEGA version 4.0 [17] with 1000 bootstrap replicates.
Reference sequences were retrieved from the HIV Sequence Database [3]. The p05MYKL045.1 genome, determined by primer walking method was
clustered closely with its primary parental isolate (shaded). (B) Bootscan plot depicting the recombination structure of p05MYKL045.1 genome.
Bootscanning analysis was performed using SimPlot version 3.5 [18] with a sliding window of 250 nucleotides overlapping by 50 nucleotides step
size. HIV-1 CRF01.93TH253 and B’.RL42 references were used as the putative parental strains, with C.95IN21068 sequence as the outlier.
doi:10.1371/journal.pone.0006666.g003
CRF33_01B Infectious Clone
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retrieved from the HIV Sequence Database [3] and included in
the analysis. Nucleotide sequences were aligned and adjusted
manually. Phylogenetic tree was plotted using neighbor-joining
method implemented in MEGA version 4.0 [17] with 1000
bootstrap replicates, and bootscanning was performed in SimPlot
version 3.5 [18] to confirm the recombination structure.
Results and Discussion
In this article, we reconstituted a chimeric infectious molecular
clone of CRF33_01B, which contains the 59 LTR derived from
p93JP-NH1. The experimental outline is depicted in Figure 1.
From approximately 100 clones of near full-length proviral DNA
generated, only one construct that replicated in HeLa cells (but
showed no infectivity in NP-2 cells) was identified, indicating the
proportions of replication-competent viral particles are low. To
rescue the molecular construct that produces non-infectious
virions, the envelope (env) gene, which plays a central role in viral
attachment, coreceptor usage and infectivity, was replaced with
potentially functional env gene from patient’s chromosomes. Sub-
genomic region that spans the tat/rev gene to the 39 LTR
downstream (approximately 3.7 kb) was amplified from the
proviral DNA by Expand Long Template PCR System using
045.tat-rev.NcoIA (59-GGC TTA GGC ATC TCC CAT GG-39;
HXB2 5954–5973) and G-EcoRI-9KU5B (59-GGA ATT C-
9KU5B-39) primers. PCR amplimers were cleaved with NcoI and
EcoRI and reconstituted into the non-replication-competent virion
producer (Figure 1). Viral replication kinetics/coreceptor usage
was then tested in NP-2 cells, and also in PBMCs. The resultant
replication-competent molecular clone was designated as
p05MYKL045.1.
Replication kinetics of p05MYKL045.1 in CD8
+ T cell-
depleted, PHA-stimulated human PBMCs showed that the peak
virus replication was achieved around day 7 and 10 post-infection
(Figure 2A). Similar viral propagations in PBMCs were also
observed for p93JP-NH1 and other control viruses. To define the
coreceptor tropism for p05MYKL045.1, viral replication was
tested in CXCR4- or CCR5-expressing CD4
+ NP-2 cells.
Microscopic examinations revealed syncytium formation in
p05MYKL045.1-infected NP-2.CD4.CXCR4 cells (Figure 2B),
but not in NP-2.CD4.CCR5 cells. Accordingly, virion-associated
RT activity was detected in the culture supernatant of NP-
2.CD4.CXCR4, but not in NP-2.CD4.CCR5 cells. The peak viral
replication was detected at day 17 post-infection (more than
25000 cpm/mlo f
32P activity) in NP-2.CD4.CXCR4 (Figure 2C).
The results also indicated that the peak viral replication for
p05MYKL045.1 was about 2-fold higher than that of the
commonly used molecular clone pNL4–3, suggesting that
p05MYKL045.1 was highly replicative in CXCR4-expressing cell
line. Together, our studies demonstrated that p05MYKL045.1 is a
CXCR4-using infectious clone that replicates competently in
PBMCs and human glioma NP-2 cells.
Next, we tested the replicative capacity of p05MYKL045.1 in
various immortalized human CD4
+ T cell lines (MT-2, M8166,
Sup-T1, H9, Jurkat, Molt-4 and PM1) and also CEMx174. No
RT production (or profound CPE) was detected for
p05MYKL045.1 virus in all cell lines (including MT-2, which is
an indicator cell line for CXCR4 tropism [19]) within 30 days
post-infection. The data suggest that p05MYKL045.1 virus can
only infect and replicate in restricted host range. Such limitations
could be due to the specific viral properties in this clone that
cannot support its propagation in human T cell lines, despite the
fact that the virus replicate well in PBMCs. We note that such
observation is not uncommon among other HIV-1 DNA
constructs. Yet undefined viral genetic factors and/or complex
interaction between viral and host factors may be involved in this
phenomenon. This includes the possibility of p05MYKL045.1
virus replicating at very low levels that rendered the RT activity
undetectable by our assay, or the relatively low level of CD4 and
coreceptors expression in these T cell lines compared to the
engineered NP-2 cells that may potentially limit p05MYKL045.1
viral infectivity [13].
The CRF33_01B genome in p05MYKL045.1 construct was
9153 bp in size, spanning all structural and regulatory genes with
intact open reading frames. Major insertions or deletions and
premature protein terminations were not present across the
genome. Phylogenetic reconstructions of the near full-length
genomes revealed that p05MYKL045.1 clustered closely with
the primary isolate (GenBank accession no. DQ366662), confirm-
ing its parental origin (Figure 3A). Bootscan plot also showed that
the recombinant structure of p05MYKL045.1 was consistent with
other CRF33_01B references, in which two short fragments of
subtype B’ were present in the gag and pol regions while the rest of
the genome was closely-related to CRF01_AE (Figure 3B) [6]. The
nucleotide sequence of p05MYKL045.1 reported in this paper has
been deposited in the GenBank database under accession number
GQ277610.
Availability of the replication-competent molecular clones that
express functional viral gene products enables systematic virolog-
ical assessment of HIV-1 subtypes/CRFs in vitro. Phenotypic and
genotypic studies that involve artificial manipulation of viral
genomes at DNA level provide significant insights on viral
replication, pathogeneses and other biological characteristics.
Despite being one of the major sites for CRF01_AE and subtype
B-based vaccine efficacy trials, the limited collection of molecular
clones of Southeast Asian origin [13,20–22] may present a
daunting challenge in developing vaccine candidates that match
the locally prevalent and diverse HIV strains especially when there
is a lack of standardized reagents for HIV neutralization assays in
clinical evaluations. As an emerging, widely distributed CRF in the
Southeast Asia region, an CRF33_01B infectious DNA clone is a
valuable tool in facilitating the development of broadly effective
vaccine candidates.
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